Credo Health's PreDx product offers a pre-encounter risk analysis, clinical summaries and HEDIS Gap Closure through an AI-enabled analysis of digital medical records, allowing healthcare providers to make more informed clinical decisions and deliver more personalized care. Through its innovative solutions, Credo is transforming healthcare, facilitating better decision-making, and driving meaningful progress in the industry.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/24 | $5,250,000 | Seed |
FCA Venture Partners FirstMile Ventures Hannah Grey SpringTime Ventures | undisclosed |
